Received Apr 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | Z5434 | — |
Havrix adult dose (0.5 ml) half of adult dose administered to pediatric patient; Havrix adult dose (0.5 ml) half of adult dose administered to pediatric patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 12-year-old male patient who received HAV (Havrix adult) (batch number Z5434, expiry date 20-SEP-2026) for prophylaxis. On 03-APR-2026, the patient received the 1st dose of Havrix adult .5 ml. On 03-APR-2026, an unknown time after receiving Havrix adult, the patient experienced adult product administered to child (Verbatim: Havrix adult dose (0.5 ml) half of adult dose administered to pediatric patient) and overdose (Verbatim: Havrix adult dose (0.5 ml) half of adult dose administered to pediatric patient). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-APR-2026 A nurse reported that one of the medical assistants in their clinic administered half of the Havrix adult dose (0.5 ml) to a pediatric patient. The nurse asked if the dose is considered valid. No further details provided.